Suruchi Kaul
Nephrology · Norwood, MANPI 1962683847
Payments from drug & device makers
Across 99 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$314
- AstraZeneca$215
- Lilly USA, LLC$162
- Bayer$145
- Novo Nordisk$136
- Pfizer$118
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,197100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $314 |
| AstraZeneca | 9 | $215 |
| Lilly USA, LLC | 7 | $162 |
| Bayer | 6 | $145 |
| Novo Nordisk | 6 | $136 |
| Pfizer | 5 | $118 |
| Shield Therapeutics Inc | 6 | $114 |
| Novartis | 4 | $90 |
| Amgen | 4 | $85 |
| Lundbeck LLC | 3 | $65 |
| Medtronic | 3 | $59 |
| Astellas Pharma US Inc | 2 | $53 |
| Johnson & Johnson | 2 | $52 |
| GRT US Holding, Inc. | 1 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Calliditas Therapeutics US Inc. | 2 | $43 |
| Viatris Specialty LLC | 2 | $37 |
| Abbott | 2 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| GSK | 1 | $33 |
| Boehringer Ingelheim | 1 | $31 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $29 |
| Amarin Pharma, Inc. | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Exact Sciences | 1 | $26 |
| Verona Pharma, Inc. | 1 | $26 |
| Eisai Inc. | 1 | $25 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Amryt Pharma Holdings Ltd | 1 | $21 |
| Merck | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Edwards Lifesciences | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
How this compares
$2,197 in reported general payments places this provider in the 65th percentile of 339 nephrology providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 31 | $32,183 |
| XareltoRivaroxaban | 12 | $6,565 |
| Metoprolol Succinate | 30 | $646 |
| Omeprazole | 31 | $603 |
| Memantine Hcl | 12 | $566 |
| Tamsulosin Hcl | 30 | $496 |
| Atorvastatin Calcium | 36 | $443 |
| Rosuvastatin Calcium | 14 | $428 |
| Amlodipine Besylate | 65 | $348 |
| Lidocaine | 14 | $319 |
| Lisinopril | 42 | $302 |
| Donepezil Hcl | 27 | $301 |
| Ezetimibe | 11 | $290 |
| Losartan Potassium | 24 | $244 |
| Hydrochlorothiazide | 33 | $219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $215 | $32,18331 claims |
| Johnson & JohnsonXarelto | $52 | $6,56512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 339 nephrology providers in Massachusetts.
Other nephrology in Norwood
- David FriedmanBoston$24.5M
- Martin PollakBoston$24.4M
- Dennis AusielloBoston$4.6M
- Subbian KarumanchiBoston$4.1M
- David ShihNorth Dartmouth$2.3M
- Anil ChandrakerWorcester$1.5M
- Jamil AzziBoston$1.4M
- Finnian McCauslandBoston$1.2M
- Meghan SiseBoston$1.2M
- Andrew AllegrettiBoston$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.